| CENTER ID: | LpboA.19690.a |
| ORGANISM: | Leptospira borgpetersenii serovar Hardjo-bovis (strain JB197) |
| ASSOCIATED DISEASE: | |
| CURRENT STATUS: | purified |
| COMMUNITY REQUEST: | True |
| NIH RISK GROUP: | 2 |
| SELECT AGENT: | False |
| NIH PRIORITY pathogens category: |
| CENTER REFERENCE ID |
DOMAIN/REGION DESCRIPTION |
INFO | AA START |
AA STOP |
ORDER MATERIAL |
|---|---|---|---|---|---|
| LpboA.19690.a.B1.GE41938 | full length | 1 | 123 | ||
| LpboA.19690.a.B2.GE42120 | PF09345 DUF | 17 | 102 |
| CENTER REFERENCE ID |
DOMAIN/REGION DESCRIPTION |
INFO | AA START |
AA STOP |
ORDER MATERIAL |
|---|---|---|---|---|---|
| LpboA.19690.a.B1.PS38516 | full length | 1 | 123 |
| METHOD | RESULTS |
|---|---|
| comparative modelling | Robetta_2684 |
| RESOURCE | REFERENCE ID |
|---|---|
| BV-BRC: | fig|355277.4.peg.2050 |
| UniProt: | Q04SF1 |
| HARVESTED ON: | 10/3/2017 |
| SEQUENCED ON: | 10/12/2017 |
| EXPECTED MW: | 15kDa |
| OBSERVED MW: | 15kDa |
| ANTIBIOTIC MARKER: | ampicillin |
| COUNT OF EXPRESSION COLONIES: | Few (1-10) |
| TOTAL EXPRESSION LEVEL: | Low Expression |
| SOLUBLE EXPRESSION LEVEL | Low Expression |
| EXPRESSION HOST: | BL 21 (DE3) Rosetta |
| SEQUENCING RESULT: | |
| PERCENT IDENTITY: | 100 |
| PERCENT COVERAGE: | 100 |
| HARVESTED ON: | 1/16/2018 |
| SEQUENCED ON: | 1/17/2018 |
| EXPECTED MW: | 11kDa |
| OBSERVED MW: | 11kDa |
| ANTIBIOTIC MARKER: | ampicillin |
| COUNT OF EXPRESSION COLONIES: | Good (10-50) |
| TOTAL EXPRESSION LEVEL: | Moderate Expression |
| SOLUBLE EXPRESSION LEVEL | Low Expression |
| EXPRESSION HOST: | BL 21 (DE3) Rosetta |
| SEQUENCING RESULT: | |
| PERCENT IDENTITY: | 100 |
| PERCENT COVERAGE: | 101 |
| PURIFICATION DATe: | 10/9/2018 |
| CONCENTRATION: | 20.33mg/ml |
| OBSERVED MW: | 15kDa |
| EXPRESSION LEVEL: | Low Expression |
| PROTEIN PURIFICATION BUFFER: | SEC: 20 mM HEPES pH 7.0, 300 mM NaCl, 5% glycerol, 1 mM TCEP |
| EXPRESSION HOST: | BL 21 (DE3) Rosetta |
| VIAL COUNT (approx.): | 3 |
| VIAL VOLUME: | 110µl |
| PERCENT IDENTITY: | 100 |
| PERCENT COVERAGE: | 100 |